Stocks Health care PLX
NYSE · Health careProtalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. brought in $80.6M of revenue over the twelve months to June 30, 2026, up 30.1% from a year earlier. Net income was $18.9M, a net margin of 23.5%. In fiscal 2025 capital spending exceeded operating cash flow by $13.6M. At June 30, 2026 it held $27.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Protalix BioTherapeutics, Inc. does
Protalix BioTherapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker PLX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $52.7M | -$6.6M | -$0.08 | -$13.6M |
| 2024 | $53.4M | $2.9M | $0.04 | $7.4M |
| 2023 | $65.5M | $8.3M | $0.09 | -$2.5M |
| 2022 | $47.6M | -$14.9M | -$0.31 | -$25.6M |
| 2021 | $38.4M | -$27.6M | -$0.62 | -$11.7M |
| 2020 | $62.9M | -$6.5M | -$0.22 | -$26.8M |
Latest SEC filings
What Protalix BioTherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 12, 2026
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026
- August 12, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 25, 2026
- May 21, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026
- May 13, 2026
- April 30, 2026
- April 30, 2026Proxy statement DEF 14A
Questions about PLX
What does Protalix BioTherapeutics, Inc. do?
Protalix BioTherapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker PLX.
Is Protalix BioTherapeutics, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $18.9M on revenue of $80.6M, a net margin of 23.5%.
How much revenue does Protalix BioTherapeutics, Inc. make?
Over the twelve months to June 30, 2026 Protalix BioTherapeutics, Inc. reported revenue of $80.6M. That is 30.1% more than a year earlier.
When did Protalix BioTherapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 9, 2026.
Similar companies
Follow PLX
Get an email when Protalix BioTherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow PLX: get an email when it filesWhere the numbers come from
Financial figures are the values Protalix BioTherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.